Bharat Biotech keen to revive Rs 600 crore TN vaccine complex

With a planned annual capacity of 585 million, the project proposed to make pentavalent, or five-in-one, combination vaccine, BCG vaccine, and vaccines to prevent measles, hepatitis B, human rabies, Hib (haemophilus influenzae type b) and Japanese encephalitis (JE) in the first phase, which was to be commissioned by 2010.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2rNWAZ6
via IFTTT